BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/29/2026 6:00:23 AM | Browse: 15 | Download: 6
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Clinical Trial |
| Article Title |
Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ke-Han Yin, Xiao-Yu Wang, Xin-Yuan Wang, Li Cheng, Bo Wang, Qian-Qian Wang, Ying Qiao, Xing-Ru Tang, Xiu-Juan Yan and Sheng-Liang Chen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82570628 |
| National Natural Science Foundation of China |
No. 82170554 |
| National Natural Science Foundation of China |
No. 82300643 |
|
| Corresponding Author |
Sheng-Liang Chen, MD, PhD, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 145 Middle Shandong Road, Shanghai 200001, China. chenslmd@shsmu.edu.cn |
| Key Words |
Non-erosive reflux disease; Neuromodulator; Lansoprazole; Flupentixol-melitracen; Symptom relief; Proton pump inhibitors |
| Core Tip |
This randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety and cost-effectiveness of low-dose flupentixol-melitracen combined with lansoprazole as an initial regimen for non-erosive reflux disease. The findings demonstrate that combining short-term, low-dose neuromodulation with a proton pump inhibitor as initial therapy in treatment-naive patients provides rapid, cost-effective symptom relief during the 12-week study period. This early-intervention strategy may help reduce symptom burden and offer a potential alternative to standard proton pump inhibitor monotherapy for patients with non-erosive reflux disease. |
| Citation |
Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; In press
|
| PDF |
122876-in-press.pdf
|
 |
Received |
|
2026-05-07 07:57 |
|
Peer-Review Started |
|
2026-05-07 07:57 |
|
First Decision by Editorial Office Director |
|
2026-05-29 08:24 |
|
Return for Revision |
|
2026-05-29 08:24 |
|
Revised |
|
2026-06-08 08:51 |
|
Publication Fee Transferred |
|
2026-06-10 12:17 |
|
Second Decision by Editor |
|
2026-06-29 02:20 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-29 06:00 |
|
Articles in Press |
|
2026-06-29 06:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
